MANHARD KIMBERLY
SEC CIK 1202094 · EDGAR
BoughtSold
Most active insiders at INBX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Viking Global Opportunities Parent GP LLC | 10% | — | $11.29M |
| 2 | Lappe Mark | CEO, Dir | $2.65M | — |
| 3 | Kayyem Jon Faiz | Dir | $1.57M | — |
| 4 | FORSYTH DOUGLAS | Dir | $286.6K | — |
| 5 | MANHARD KIMBERLY | Dir | — | $279.0K |
Transactions 22
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2026-09-15 17:52 | 2026-09-11+ | INBX | Inhibrx Biosciences, Inc. | MANHARD KIMBERLY | Dir | S - Sale | $109.03 | -1,500 | 7,500 | -17% | -$163.5K |
| MI | 2026-09-10 19:06 | 2026-09-08+ | INBX | Inhibrx Biosciences, Inc. | MANHARD KIMBERLY | Dir | S - Sale | $115.47 | -1,000 | 9,000 | -10% | -$115.5K |
| I | 2024-08-30 | 2024-08-28 | INBX | Inhibrx Biosciences, Inc. | MANHARD KIMBERLY | Dir | P - Purchase | $13.98 | +10.0K | 10.0K | New | +$139.8K |
| DM | 2023-04-17 | 2023-04-13 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development | M - OptEx | — | +5,814 | 29.7K | +24% | — |
| D | 2023-04-17 | 2023-04-13 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development | F - Tax | $2.88 | -1,417 | 28.3K | -5% | -$4,081 |
| D | 2023-01-17 | 2023-01-13 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development, Dir | F - Tax | $3.17 | -2,012 | 23.9K | -8% | -$6,378 |
| DM | 2023-01-17 | 2023-01-13 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development, Dir | M - OptEx | — | +5,814 | 25.9K | +29% | — |
| D | 2023-01-17 | 2022-10-31 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development, Dir | J - Other | $3.27 | +1,655 | 20.1K | +9% | +$5,412 |
| DM | 2022-10-17 | 2022-10-13 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development, Dir | M - OptEx | — | +5,814 | 20.5K | +40% | — |
| D | 2022-10-17 | 2022-10-13 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development, Dir | F - Tax | $3.76 | -2,012 | 18.5K | -10% | -$7,565 |
| DM | 2022-07-15 | 2022-07-13 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development, Dir | M - OptEx | — | +5,814 | 16.7K | +53% | — |
| D | 2022-07-15 | 2022-07-13 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development, Dir | F - Tax | $3.01 | -2,012 | 14.7K | -12% | -$6,056 |
| 2022-05-04 | 2022-05-03 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development, Dir | S - Sale | $4.76 | -1,504 | 10.9K | -12% | -$7,159 | |
| 2022-05-04 | 2022-04-29 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development, Dir | J - Other | $3.84 | +1,504 | 12.4K | +14% | +$5,775 | |
| DM | 2022-04-15 | 2022-04-13 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development, Dir | M - OptEx | — | +5,814 | 8,320 | +232% | — |
| D | 2022-04-15 | 2022-04-13 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development, Dir | F - Tax | $6.07 | -2,012 | 10.9K | -16% | -$12.2K |
| D | 2022-01-14 | 2022-01-13 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development, Dir | F - Tax | $8.30 | -2,012 | 7,070 | -22% | -$16.7K |
| DM | 2022-01-14 | 2022-01-13 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development, Dir | M - OptEx | — | +5,814 | 4,518 | New | — |
| D | 2021-10-15 | 2021-10-13 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development, Dir | M - OptEx | — | +1,250 | 3,701 | +51% | — |
| D | 2021-10-15 | 2021-10-13 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development, Dir | F - Tax | $10.55 | -433 | 3,268 | -12% | -$4,568 |
| D | 2021-07-15 | 2021-07-13 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development, Dir | M - OptEx | — | +1,250 | 2,884 | +76% | — |
| D | 2021-07-15 | 2021-07-13 | HRTX | HERON THERAPEUTICS, INC. /DE/ | MANHARD KIMBERLY | EVP, Drug Development, Dir | F - Tax | $13.48 | -433 | 2,451 | -15% | -$5,837 |
Purchase Sale Sale after option exercise All abbreviations